Effects of Essential Amino Acid Intake on Net Protein Synthesis in Weight-losing Non-small Cell Lung Cancer Patients
Weight loss commonly occurs in lung cancer patients, negatively influencing their quality of life, treatment response and survival. Gains in lean body mass are difficult to achieve in cancer unless specific metabolic abnormalities are targeted. It is our hypothesis that a nutritional supplement containing a high amount of essential amino acids will target the metabolic alterations of cancer patients. Preliminary research performed in our laboratory in elderly supports this hypothesis. We hypothesize that intake of an essential amino acid nutritional supplement will positively influence protein synthesis rate in advanced non-small cell lung cancer (NSCLC) patients. Furthermore, insight in the underlying mechanism of the higher anabolic response of the essential amino acid supplement will be examined. This information will potentially enable us to formulate a supplement that is more effective than normal food intake, and that will reduce the need for muscle protein breakdown.
Checked against the public recordLast updated Sep 30, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Other
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Texas A&M University
- Interventions being studied
- Dietary Supplement: EAA+LEU vs total AA; Dietary Supplement: Total AA vs EAA+LEU
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Recently diagnosed with Stage III (unresectable) or Stage IV lung cancer (only for the NSCLC group) 2. Ability to sign informed consent 3. Age 40 years and older Exclusion Criteria: 1. Previous anti-cancer therapy (e.g. radiotherapy, chemotherapy) or surgery less than 4 weeks prior to the experiment. 2. Presence of fever within the last 3 days 3. Established diagnosis of Diabetes Mellitus 4. BMI \> 35 kg/m2 5. Untreated metabolic diseases including hepatic or renal disorder 6. Presence of acute illness or metabolically unstable chronic illness 7. Use of long-term oral corticosteroids or short course of oral corticosteroids in the preceding month before enrollment 8. Diagnosis of moderate to severe chronic airflow limitation, defined as measured forced expiratory volume in one second (FEV1) ≤ 70% of referen¬ce FEV1 (only for the healthy control group) 9. Use of supplements enriched with amino acids 10. Any other condition according to the PI or study physicians would interfere with proper conduct of the study / safety of the patient 11. Failure to give informed consent
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Arkansas for Medical SciencesLittle Rock, Arkansas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 30, 2025. Always confirm current availability with the study team.